107 related articles for article (PubMed ID: 10155092)
1. Early and late ischemic complications of PTCA.
Ferguson JJ; Wilson JM
J Invasive Cardiol; 1994; 6 Suppl A():3A-12A, discussion 43A-45A. PubMed ID: 10155092
[No Abstract] [Full Text] [Related]
2. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
[TBL] [Abstract][Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa receptor inhibitors: is their future as bright as their past?
Leesar MA
Catheter Cardiovasc Interv; 2008 Jun; 71(7):907-8. PubMed ID: 18498141
[No Abstract] [Full Text] [Related]
4. It is never too late for PCI: To relieve medically refractory myocardial ischemia.
Morrison DA
Catheter Cardiovasc Interv; 2009 Mar; 73(4):455-6. PubMed ID: 19235234
[No Abstract] [Full Text] [Related]
5. Myocardial protection with a beta blocker and glycoprotein IIb/IIIa inhibitor during PCI: attractive concept, but limited evidence of benefit.
Leesar MA
Catheter Cardiovasc Interv; 2008 Oct; 72(4):498-9. PubMed ID: 18819148
[No Abstract] [Full Text] [Related]
6. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Gurbel PA
Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb-IIIa inhibitors in unstable coronary syndromes and percutaneous interventions--a conservative approach.
De Caterina R; Di Gioacchino L
Rev Port Cardiol; 2003; 22(7-8):995-1002. PubMed ID: 14587167
[TBL] [Abstract][Full Text] [Related]
8. Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis?
Lemos PA
Catheter Cardiovasc Interv; 2007 Jun; 69(7):959-60. PubMed ID: 17525956
[No Abstract] [Full Text] [Related]
9. Landmarks: examining the foundation for GP IIb/IIIa inhibitors in PCI.
J Invasive Cardiol; 2002 Dec; 14(12):776-9. PubMed ID: 12537005
[No Abstract] [Full Text] [Related]
10. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
11. The evolving role of glycoprotein (GP) IIb/IIIa receptor blockade during percutaneous coronary intervention of saphenous vein bypass grafts.
D'Agate DJ; Patel S; Coppola JT; Ambrose JA
J Invasive Cardiol; 2004 Sep; 16(9):500-3. PubMed ID: 15353833
[No Abstract] [Full Text] [Related]
12. Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?
Piamsomboon C; Wong PM; Mathur A; Singh D; Liu MW; Baxley WA; Iyer SS; Dean LS; Roubin GS
Catheter Cardiovasc Interv; 1999 Apr; 46(4):415-20. PubMed ID: 10216005
[TBL] [Abstract][Full Text] [Related]
13. [Percutaneous coronary intervention].
Csapó K
Orv Hetil; 2005 Mar; 146(13):587-93. PubMed ID: 15856622
[TBL] [Abstract][Full Text] [Related]
14. Diabetes and percutaneous coronary intervention: the sweet smell of success?
Quinn MJ; Moliterno DJ
Am Heart J; 2003 Feb; 145(2):203-5. PubMed ID: 12595833
[No Abstract] [Full Text] [Related]
15. TCT Daily: ESTROFA: late thrombosis not increased in DES patients: Spanish registry of drug-eluting stents shows STEMI, LAD artery lesions, significant risk factors.
Kahn J
J Interv Cardiol; 2007 Feb; 20(1):32. PubMed ID: 17300396
[No Abstract] [Full Text] [Related]
16. Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery.
Cheng DK; Jackevicius CA; Seidelin P; Feindel C; Rouleau JL
Can J Cardiol; 2004 Feb; 20(2):223-8. PubMed ID: 15010747
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor use.
Sabatine MS; Hamdalla HN; Mehta SR; Fox KA; Topol EJ; Steinhubl SR; Cannon CP
Am Heart J; 2008 May; 155(5):910-7. PubMed ID: 18440341
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous integrin alphavbeta3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty.
Sakuma T; Sari I; Goodman CN; Lindner JR; Klibanov AL; Kaul S
Cardiovasc Res; 2005 Jun; 66(3):552-61. PubMed ID: 15914120
[TBL] [Abstract][Full Text] [Related]
19. Letter regarding article by Hlatky et al, "medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease".
Osman F; Qaisar S; Pitt M
Circulation; 2005 Apr; 111(13):e176-7; author reply e176-7. PubMed ID: 15811864
[No Abstract] [Full Text] [Related]
20. High incidence of recurrent in stent thrombosis after successful treatment of a first in stent thrombosis.
Lemesle G; Sudre A; Modine T; Delhaye C; Rosey G; Gourlay T; Bauters C; Lablanche JM
Catheter Cardiovasc Interv; 2008 Oct; 72(4):470-8. PubMed ID: 18814219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
